AbbVie (ABBV) reports Q3 earnings Wednesday. The acquisition of Aliada Therapeutics may boost its Alzheimer's portfolio and ...

In trading on Monday, shares of AbbVie crossed below their 200 day moving average of $178.81, changing hands as low as $172.70 per share. AbbVie Inc shares are currently trading down about 12.4% ...

For years, AbbVie's (ABBV) blockbuster rheumatoid-arthritis ... according to the World Health Organization. People with ...

Valuation metrics show AbbVie to be only slightly undervalued based on FY 2025 projections. With Humira revenue degrading, it would be wise to wait for evidence of a revenue replacement before ...